Ezetimibe

Ezetimibe has been studied in 228 papers since 2006: 25 trials and 95 observational studies in people, 3 in animals, 82 reviews; 160 in the past year. It is an approved medicine. The newest story, Nov 9, 2026: “Evolocumab linked to fewer deaths in high-risk adults”.

InterventionApproved 2002

228 papers study it67 more mention it53 findingsUpdated

PubChemChEBIMeSH

104 new papers in 30 daysSee all 294 papers on ezetimibe

At a glance

Ezetimibe extends lifespan in one SR-BI/apoE dKO mouse study; independent labs report human LDL lowering. An observational study links use with lower mortality in statin-treated people with type 2 diabetes versus statins alone, but a trial shows no clear mortality effect. Papers declare company ties; across all uses, many trials ended over a year ago without posted results.

53 findings in 33 papers from 2006 to 2026, 15 of them since July 2026

Independent labs found the same change in people. 27 independent labs in 13 countries; 300 trials, 128 about aging, 153 with no results posted.

“Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% CI, 0.50-0.86; P=0.002).”
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled TrialCirculation2019doi:10.1161/circulationaha.118.039415

1 of its findings points the other way.

Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
  • 27 independent labs in 13 countries
  • 1 finding against
  • 300 trials, 128 about aging, 153 with no results posted
  • Funders: National Institutes of Health and others
  • 11 of 48 findings with company ties
  • 95 of 300 trials sponsored by its developers
  • Human trial25
  • Humans94
  • Animals3
  • In silico9

9 studies gave ezetimibe to people and measured what changed.

What changedDesignPeopleSource

up: Increases PTPRS expression

Randomized trial4 weeksBritish journal of pharmacology, Nov 10, 2026

no change: Has no effect on number of plaque vulnerability criteria

down: Decreases LDL cholesterol

Randomized trial52 weeks125 peopleBoth59 (51; 64) yearsPatients with acute coronary syndrome not achieving LDL-cholesterol target with statin therapyJournal of clinical medicine, Sep 29, 2026

down: Decreases non-HDL cholesterolΔ -76.0 versus -66.0 mg/dL; P=0.047

down: Decreases statin-associated muscle symptoms0.7% versus 5.4%; P=0.021

no change: Has no effect on new-onset diabetes5.1% versus 14.5%; P=0.065

Randomized trial6 months318 people≥70 yearsOlder adults; Patient cohortsJournal of the American Heart Association, Jul 3, 2026

down: Decreases IgG apoB-containing immune complexes-17.5%

Trial3 months70 people40% were male51 ± 15 yearsConsecutive adult patients with Lp(a) levels ≥ 75 nmol/LClinical research in cardiology : official journal of the German Cardiac Society, Mar 23, 2026

down: Decreases primary composite cardiovascular outcomeHR 0.66, 95% CI 0.50-0.86

down: Decreases composite cardiac eventsHR 0.60, 95% CI 0.37-0.98

down: Decreases coronary revascularizationHR 0.38, 95% CI 0.18-0.79

Randomized trialmedian follow-up 4.1 years3,796 peopleBoth75 years or olderOlder adults; primary prevention in patients aged 75 or older without coronary artery diseaseCirculation, Aug 22, 2019

What did studies of ezetimibe find?

32

Studies of ezetimibe measured 32 outcomes; the most studied is LDL cholesterol (4 studies).

LDL cholesterol

downin humans4

4 studies
  1. Ezetimibe decreases LDL cholesterol in humans (Ataxia-telangiectasia with severe mixed atherogenic dyslipidemia) (174 to 149 mg/dL).

    “Ezetimibe lowered low-density lipoprotein cholesterol from 174 to 149 mg/dL.”

    Human trialAtaxia-telangiectasia with severe mixed atherogenic dyslipidemiafemalesn = 1

    Severe Atherogenic Dyslipidemia in Ataxia-Telangiectasia Despite Cachexia: Mechanistic Insights into Mitochondrial Dysfunction

    The Yale journal of biology and medicine

  2. Ezetimibe decreases LDL cholesterol in humans.

    “In the Ezetimibe group, the median LDL-C level decreased from 1.96 (1.76–2.44) to 1.49 (1.36–1.79) mmol/L (p < 0.001), while in the Alirocumab group, it decreased from 2.35 (2.08–2.92) to 1.33 (1.09–1.70) mmol/L (p = 0.001).”

    Human trial52 weeksn = 64

    Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial

    Journal of clinical medicine

  3. Ezetimibe decreases LDL cholesterol in monotherapy.

    “The comparison of the two treatments in terms of percent lipid variations showed that BBR/P/RR was more effective than EZE in reducing TC, LDL-C and non-HDL-C levels, and showed a tendency to lower TG more than EZE.”

    Human trialin monotherapysix monthsn = 76

    Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

    Lipids in health and disease

  4. Ezetimibe is linked with lower LDL cholesterol in humans (added to background moderate-intensity statin therapy, compared with bempedoic acid) (greater LDL-C reduction than bempedoic acid; no values stated).

    “Low-density lipoprotein cholesterol (LDL-C) reduction was greater with ezetimibe.”

    Humansadded to background moderate-intensity statin therapy, compared with bempedoic acidn = 6,706

    Bempedoic acid vs ezetimibe added to statin therapy: Cardiovascular outcomes in the real-world-The BEYOND-REAL Study

    Journal of clinical lipidology

More on LDL cholesterol

PTPRS expression

upin human cells1

1 study
  1. Ezetimibe increases PTPRS expression in human cells.

    “In SOAT2‐only‐HepG2 cells, selected predictions were supported experimentally, including APOA2 induction and ezetimibe‐associated PTPRS upregulation.”

    CellsSOAT2-only-HepG2

    Interpretable multimodal network analysis of lipid‐lowering therapies

    British journal of pharmacology

More on PTPRS expression

Lipoprotein

no changein humans1

1 study
  1. Ezetimibe showed no clear effect on lipoprotein in humans (Compared with control in pooled randomized controlled trials) (MD 1.20%; 95% CI −3.04 to 5.44).

    “Ezetimibe showed no significant effect on Lp(a) (MD, 1.20%; 95% CI, –3.04 to 5.44).”

    ReviewCompared with control in pooled randomized controlled trials

    Comparative Effects of Lipoprotein(a)-Targeted and Lipid-Modifying Therapies on Percent Change in Lipoprotein(a)

    AHA Scientific Sessions 2026 abstract

More on Lipoprotein

LDL-C target achievement

upin humans1OR 6.17

1 study
  1. Ezetimibe is linked with higher LDL-C target achievement in humans (added to high-intensity statin at discharge vs statin monotherapy in LDL-PMF patients) (OR 6.17, 95% CI 2.78–13.71; 65% vs. 27% reached target).

    “ezetimibe use was the strongest independent predictor of reaching the target (OR 6.17, 95% CI: 2.78–13.71; p < 0.001)”

    Humansadded to high-intensity statin at discharge vs statin monotherapy in LDL-PMF patients3 monthsn = 211

    Upfront combination lipid-lowering therapy in statin-naive acute coronary syndrome patients with high admission LDL-C: real-world support for the 2025 ESC dyslipidaemias guidelines

    ESC Congress 2026 abstract

More on LDL-C target achievement

Linoleic acid

downin humans1

1 study
  1. Ezetimibe is linked with lower linoleic acid in humans (genetically proxied NPC1L1 inhibition in individuals of European descent).

    “All three most clearly and consistently reduced polyunsaturated fatty acids, omega-6 and linoleic acid (LA)”

    Humansgenetically proxied NPC1L1 inhibition in individuals of European descent

    Effects of Major Lipid-Lowering Drug Targets on Circulating Fatty Acids: A Mendelian Randomization Study

    Genes

More on Linoleic acid

Number of plaque vulnerability criteria

no changein humans1

1 study
  1. Ezetimibe showed no clear effect on number of plaque vulnerability criteria in humans.

    “Direct comparison of the changes between the groups revealed no statistically significant differences in the number of vulnerability criteria (p = 0.930), and no statistically significant between-group differences in the number of vulnerable plaques (p = 0.894).”

    Human trial52 weeksn = 64

    Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial

    Journal of clinical medicine

Cardiovascular disease mortality

downin humans1

1 study
  1. Ezetimibe decreases cardiovascular disease mortality in humans (network meta-analysis of CVD-related mortality).

    “Ezetimibe demonstrated the most favorable safety profile for reducing CVD mortality”

    Reviewnetwork meta-analysis of CVD-related mortalityn = 43,625

    Safety and efficacy of low-density lipoprotein-lowering drugs in the elderly: a network meta-analysis of randomized controlled trials

    Journal of geriatric cardiology : JGC

Ezetimibe prescription use

upin humans1

1 study
  1. Ezetimibe is linked with higher ezetimibe prescription use in humans (prescription patterns among people with dyslipidemia) (approximately four-fold).

    “Ezetimibe use increased approximately four-fold, while fibrate use remained relatively unchanged.”

    Humansprescription patterns among people with dyslipidemia2010-2019

    Cardiovascular Disease Incidence and Lipid-Lowering Medication Use in Korean Adults With Dyslipidemia: A Nationwide Population-Based Retrospective Cohort Study From 2010 to 2019

    Journal of lipid and atherosclerosis

New-onset diabetes

no changein humans1

1 study
  1. Ezetimibe showed no clear effect on new-onset diabetes in humans (combined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapy) (5.1% versus 14.5%; P=0.065).

    “New-onset diabetes did not differ significantly between groups (5.1% versus 14.5%; P=0.065)”

    Human trialcombined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapyrosuvastatin 5 mg/ezetimibe 10 mg6 monthsn = 318

    Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients

    Journal of the American Heart Association

More on New-onset diabetes

Statin-associated muscle symptoms

downin humans1

1 study
  1. Ezetimibe decreases statin-associated muscle symptoms in humans (combined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapy) (0.7% versus 5.4%; P=0.021).

    “Statin-associated muscle symptoms occurred less frequently with combination therapy (0.7% versus 5.4%; P=0.021).”

    Human trialcombined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapyrosuvastatin 5 mg/ezetimibe 10 mg6 monthsn = 318

    Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients

    Journal of the American Heart Association

More on Statin-associated muscle symptoms

Non-HDL cholesterol

downin humans1

1 study
  1. Ezetimibe decreases non-HDL cholesterol in humans (combined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapy) (Δ -76.0 versus -66.0 mg/dL; P=0.047).

    “Combination therapy achieved greater non-high-density lipoprotein cholesterol reduction (Δ -76.0 versus -66.0 mg/dL; P=0.047)”

    Human trialcombined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapyrosuvastatin 5 mg/ezetimibe 10 mg6 monthsn = 318

    Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients

    Journal of the American Heart Association

More on Non-HDL cholesterol

IgG apoB-containing immune complexes

downin humans1−18%

1 study
  1. Ezetimibe decreases IgG apoB-containing immune complexes in humans (added to high-intensity statin) (-17.5%).

    “Significant reductions in IgG apoB-IC levels were observed following treatment with high-intensity statins, add-on ezetimibe and add-on PCSK9i (by 18.3%, 17.5% and 25.5%, respectively, all p < 0.05).”

    Human trialadded to high-intensity statin3 monthsn = 31

    Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a)

    Clinical research in cardiology : official journal of the German Cardiac Society

More on IgG apoB-containing immune complexes

C-reactive protein

no changein humans1

1 study
  1. Ezetimibe showed no clear effect on C-reactive protein in humans (on background PCSK9 inhibitor therapy).

    “In the ezetimibe group, LDL-C decreased by 70% (p<0.01) with no reduction in hsCRP.”

    Human trialon background PCSK9 inhibitor therapy10 mg1 month

    Direct Vascular Endothelial Assessment Highlights the Pleotropic Anti-Inflammatory Properties of Statin Therapy: Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network

    AHA Scientific Sessions 2025 abstract

More on C-reactive protein

Mortality

no changein humans1

1 study
  1. Ezetimibe showed no clear effect on mortality in humans.

    “there was no difference in the incidence of stroke, all-cause mortality, or adverse events between trial groups”

    Human trial

    Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial

    Circulation

Stroke

no changein humans1

1 study
  1. Ezetimibe showed no clear effect on stroke in humans.

    “there was no difference in the incidence of stroke, all-cause mortality, or adverse events between trial groups”

    Human trial

    Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial

    Circulation

More on Stroke

All 32

What is ezetimibe linked with?

16

Studies link ezetimibe with 16 measures, among them LDL-C target attainment, cancer-related mortality and cardiovascular events.

LDL-C target attainment

upin humans2OR 2.64–5.28

2 studies
  1. Ezetimibe is associated with LDL-C target attainment in humans (OR 5.28; 95% CI 1.31-21.32).

    “ezetimibe use in addition to high-intensity statin therapy at discharge (OR 5.28; 95% CI 1.31-21.32) were associated with LDL-C target attainment.”

    HumansAdded to high-intensity statin therapy at discharge after a first acute coronary syndrome; multivariable modelMedian 5 weeks (IQR, 4-6)Both; 70.7% malesn = 82

    Lipoprotein(a) and early LDL-cholesterol target attainment after a first acute coronary syndrome: a real-world cohort study

    Atherosclerosis plus

  2. Ezetimibe is associated with LDL-C target attainment in humans (established atherosclerotic cardiovascular disease) (OR = 2.64).

    “Independent predictors of target attainment included PCSK9 inhibitor therapy (OR = 7.65), high-intensity statins (OR = 4.73), ezetimibe (OR = 2.64)”

    Humansestablished atherosclerotic cardiovascular diseasen = 1,904

    Extreme cardiovascular risk as a major barrier to LDL-C target achievement: insights from ITACARE-P registry

    Nutrition, metabolism, and cardiovascular diseases : NMCD

More on LDL-C target attainment

Cancer-related mortality

downin humans2HR 0.8–0.85

2 studies
  1. Ezetimibe is linked with a lower risk of cancer-related mortality in humans (compared with statin monotherapy) (HR 0.85).

    “ezetimibe-statin combination therapy was associated with a significantly lower risk of cancer (hazard ratio [HR], 0.89; P<0.001) and cancer-related mortality (HR, 0.85; P<0.001)”

    Humanscompared with statin monotherapyezetimibe-statin combination therapyn = 669,036

    Ezetimibe Treatment Is Associated with Lower Risk of Incident Cancer: A Nationwide Population-Based Cohort Study

    Endocrinology and metabolism (Seoul, Korea)

  2. Ezetimibe is linked with a lower risk of cancer-related mortality in statin users with type 2 diabetes, versus statin monotherapy (HR 0.80; P<0.001).

    “significantly lower risk of incident cancer (HR 0.88; P<0.001), cancer-related mortality (HR 0.80; P<0.001), and all-cause mortality (HR 0.92; P=0.033)”

    Humansin statin users with type 2 diabetes, versus statin monotherapyn = 89,866

    Combination Lipid-Lowering Therapy and the Risks of Various Types of Cancers in Patients with Type 2 Diabetes

    ADA Scientific Sessions 2025 abstract

Cardiovascular events

downin humans1

1 study
  1. Ezetimibe lowers the risk of cardiovascular events in humans (coronary atherosclerosis).

    “Statins, ezetimibe, bempedoic acid and PCSK9 monoclonal antibodies reduce cardiovascular events by lowering atherogenic lipoprotein exposure.”

    Reviewcoronary atherosclerosis

    Pharmacotherapy for coronary atherosclerosis: from lipid lowering to plaque stabilization and repair

    Frontiers in cardiovascular medicine

LDL cholesterol

downin humans1

1 study
  1. Ezetimibe is associated with LDL cholesterol in humans (Change from baseline in statin-intolerant patients receiving GLP-1 receptor agonists) (18.0 mg/dL reduction from baseline; 104.1 to 86.1 mg/dL).

    “mean LDL-C decreased to 86.1 mg/dL in the ezetimibe cohort (Absolute Reduction (AR) = 18.0 mg/dL)”

    HumansChange from baseline in statin-intolerant patients receiving GLP-1 receptor agonists1 yearn = 748

    Bempedoic Acid versus Ezetimibe for Secondary Prevention in Statin-Intolerant Patients with Cardiovascular-Kidney-Metabolic Syndrome Taking Glucagon-Like Peptide-1 Receptor Agonists

    AHA Scientific Sessions 2026 abstract

More on LDL cholesterol

≥30% LDL-C reduction

upin humans1

1 study
  1. Ezetimibe is associated with ≥30% LDL-C reduction in humans Among bempedoic acid users; multivariable-adjusted association (aOR 1.81, 95% CI 1.55–2.11).

    “EZE use in the 30 days pre-index (aOR[CI 95% ]: 1.81 [1.55-2.11]) was associated with greater likelihood of achieving ≥30% LDL-C reduction.”

    HumansAmong bempedoic acid users; multivariable-adjusted associationEzetimibe use in the 30 days pre-indexn = 3,204

    Factors Associated with Enhanced LDL-C Lowering with Bempedoic Acid and Bempedoic Acid Plus Ezetimibe in Routine Practice

    AHA Scientific Sessions 2026 abstract

More on ≥30% LDL-C reduction

Cancer

downin humans1HR 0.89

1 study
  1. Ezetimibe is linked with a lower risk of cancer in humans (compared with statin monotherapy) (HR 0.89).

    “ezetimibe-statin combination therapy was associated with a significantly lower risk of cancer (hazard ratio [HR], 0.89; P<0.001)”

    Humanscompared with statin monotherapyezetimibe-statin combination therapyn = 669,036

    Ezetimibe Treatment Is Associated with Lower Risk of Incident Cancer: A Nationwide Population-Based Cohort Study

    Endocrinology and metabolism (Seoul, Korea)

More on Cancer

Focal epilepsy, lesion negative

upin humans1OR 1.08

1 study
  1. Ezetimibe is linked with a higher risk of focal epilepsy, lesion negative in humans (genetically proxied NPC1L1 inhibition (Mendelian randomization)) (OR 1.08 (95% CI 1.06–1.09); P = 5.9 × 10-31).

    “but increased risks of focal epilepsy (lesion negative, OR = 1.08; 95% CI: 1.06-1.09; P = 5.9 × 10-31)”

    Humansgenetically proxied NPC1L1 inhibition (Mendelian randomization)

    Effects of lipid-lowering drugs on epilepsy and its subtypes: A drug-target Mendelian randomization study

    Medicine

More on Focal epilepsy, lesion negative

Generalized epilepsy with tonic-clonic seizures

downin humans1OR 0.98

1 study
  1. Ezetimibe is linked with a lower risk of generalized epilepsy with tonic-clonic seizures in humans (genetically proxied NPC1L1 inhibition (Mendelian randomization)) (OR 0.98 (95% CI 0.97–0.98); P = 1.2 × 10-34).

    “Inhibition of Niemann-Pick C1-Like 1 corresponded to a lower risk of generalized epilepsy with tonic-clonic seizures (OR = 0.98; 95% CI: 0.97-0.98; P = 1.2 × 10-34)”

    Humansgenetically proxied NPC1L1 inhibition (Mendelian randomization)

    Effects of lipid-lowering drugs on epilepsy and its subtypes: A drug-target Mendelian randomization study

    Medicine

More on Generalized epilepsy with tonic-clonic seizures

Atherosclerotic cardiovascular disease events

downin humans1

1 study
  1. Ezetimibe lowers the risk of atherosclerotic cardiovascular disease events in humans (without statin therapy and without a history of coronary artery disease).

    “supports the reduction in the risk of atherosclerotic cardiovascular disease (ASCVD) events with ezetimibe without statin therapy in persons aged ≥75 years”

    Reviewwithout statin therapy and without a history of coronary artery disease

    Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events

    Annals of medicine

More on Atherosclerotic cardiovascular disease events

Amnesia

upin humans1

1 study
  1. Ezetimibe is linked with a higher risk of amnesia in humans (ROR = 1.55, 95% CI 1.20-2.00).

    “Ezetimibe showed a positive signal for "amnesia" (ROR = 1.55, 95% CI 1.20-2.00) but an inverse association against "memory impairment" (ROR = 0.50, 95% CI 0.37-0.69).”

    Humansn = 100

    Association between three lipid-lowering drugs and amnesia: a real-world pharmacovigilance study

    Naunyn-Schmiedeberg's archives of pharmacology

More on Amnesia

All 16

Has ezetimibe been tested in people?

128 of 300 about aging

Yes: 25 trials and 95 observational studies in people have been published, and 223 trials are registered.

Approved

  • FDA Zetia

    Oct 25, 2002Homozygous Familial Hypercholesterolemia, Sitosterolemia, heterozygous familial hypercholesterolemia, Hyperlipidemia, mixed hyperlipidemia, primary hyperlipidemia

Repurposing

40 of 51

Every condition in trials

  • Hyperlipidemias

    Phase 4Completed15 trials

  • Nutritional and metabolic disease

    Phase 4Completed1 trial

  • Hyperlipoproteinemia type II

    Phase 3Results posted8 trials

  • Inborn errors lipid metabolism

    Phase 3Completed3 trials

  • Cholesterol

    Phase 3Completed1 trial

  • Hypercholerolemia

    Phase 3Completed1 trial

All 11

Stopped

  • NCT00651014TerminatedHypercholesterolemia

    slow subject recruitment and lack of medical and scientific merit due to change in new standard of therapy during that same period.

  • NCT02971033TerminatedChronic hepatitis C

    Study Funding ended

Who is developing ezetimibe?

3 companies: Berlin Pharmaceutical Industry, JW Pharmaceutical and Organon.

Companies
  • Berlin Pharmaceutical IndustryPhase 4hypercholesterolemia in high or very high cardiovascular risk patients rosuvastatin, ezetimibe, hypercholesterolemia, dyslipidemia, cardiovascular diseases, LDL cholesterol, rosuvastatin, ezetimibe, hypercholesterolemia, dyslipidemia, cardiovascular diseases, LDL cholesterol
  • JW PharmaceuticalPhase 4hypercholesterolemia
  • OrganonPhase 4atherosclerosis, hypercholesterolemia

Trial sponsors

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 6Jan 2026: 17Feb 2026: 22Mar 2026: 9Apr 2026: 1May 2026: 4Jun 2026: 5Jul 2026: 6Aug 2026: 17Sep 2026: 20Oct 2026: 62Nov 2026: 42211 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Cohort studyEvolocumab

See all 294 papers on ezetimibe